Breast cancer and sphingolipid signalling

Journal of Dairy Research

Volumn 72, Issue SPEC. ISS., 2005, Pages 5-13

  Signorelli, Paola ^a   Ghidoni, Riccardo ^a  

^a SAN PAOLO HOSPITAL   (Italy)

Author keywords

Cancer; Ceramide; Sphingosine

Indexed keywords

ANTINEOPLASTIC AGENT; CERAMIDE; SPHINGOLIPID;

BREAST TUMOR; DRUG RESISTANCE; FEMALE; HUMAN; METABOLISM; METASTASIS; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CERAMIDES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 24944454974     PISSN: 00220299     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0022029905001238     Document Type: Review

References (106)

1. Ameyar M, Atfi A, Cai Z, Stancou R, Shatrov V, Bettaieb A & Chouaib S 1998 Analysis of human breast adenocarcinoma MCF7 resistance to tumor necrosis factor-induced cell death. Lack of correlation between JNK activation and ceramide pathway. Journal of Biological Chemistry 273 29002-29008
2. Andres AC & Strange R 1999 Apoptosis in the oestrous and menstrual cycles. Journal of Mammary Gland Biology and Neoplasia 4 221-228
3. Aoyama Y 2002 Experimental studies on the effects of the combined use of N-(4-hydroxyphenyl)retinamide (4-HPR) and tamoxifen (TAM) for estrogen receptor (ER)-negative breast cancer. Kurume Medicine Journal 49 27-33
4. Basu M, Dastgheib S, Girzadas MA, O'Donnell PH, Westervelt CW, Li Z, Inokuchi J, Basu S 1998 Hydrophobic nature of mammalian ceramide glycanases: purified from rabbit and rat mammary tissues. Acta Biochimica Polonica 45 327-342
5. Basu M, Girzadas M, Dastgheib S, Baker J, Rossi F, Radin NS & Basu S 1997 Ceramide glycanase from rat mammary tissues: inhibition by PPMP(D-/L-) and its probable role in signal transduction. Indian Journal of Biochemica and Biophysica 34 142-149
6. Basu M, Kelly P, Girzadas M, Li Z & Basu S 2000 Properties of animal ceramide glycanases. Methods in Enzymology 311 287-297
7. Becker KP, Kitatani K, Idkowiak-Baldys J, Bielawski J & Hannun YA 2004 Selective inhibition of juxtanuclear translocation of PKC {beta}II by a negative feedback mechanism involving ceramide formed from the salvage pathway. Journal of Biological Chemistry 280 2606-2612
8. Birbes H, Luberto C, Hsu YT, Bawab SE, Hannun YA & Obeid LM 2005 A mitochondrial pool of sphingomyelin is involved in TNFalpha-induced Bax translocation to mitochondria. Biochemical Journal 386 445-451
9. Biswal SS, Datta K, Acquaah-Mensah GK & Kehrer JP 2000 Changes in ceramide and sphingomyelin following fludarabine treatment of human chronic B-cell leukemia cells. Toxicology 154 45-53
10. Bleicher RJ & Cabot MC 2002 Clucosylceramide synthase and apoptosis. Biochimica et Biophysica Acta 1585 172-178
11. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z & Kolesnick R 1995 Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82 405-414
12. Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, Hammond TG, Clejan S & Beckman BS 1998 Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Research 58 4940-4946
13. Cai Z, Bettaieb A, Mahdani NE, Legres LG, Stancou R, Masliah J & Chouaib S 1997 Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor-alpha-mediated cytotoxicity. Journal of Biological Chemistry 272 6918-6926
14. Callaghan R & Higgins CF 1995 Interaction of tamoxifen with the multidrug resistance P-glycoprotein. British Journal of Cancer 71 294-299
15. Castro AF, Horton JK, Vanoye CG & Altenberg GA 1999 Mechanism of inhibition of P-glycoprotein-mediated drug transport by protein kinase C blockers. Biochemical Pharmacology 58 1723-1733
16. Chalfant CE, Rathman K, Pinkerman RL, Wood RE, Obeid LM, Ogretmen B & Hannun YA 2002 De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. Journal of Biological Chemistry 277 12587-12595
17. Charles AG, Han TY, Liu YY, Hansen N, Giuliano AE & Cabot MC 2001 Taxol-induced ceramide generation and apoptosis in human breast cancer cells. Cancer Chemotherapy and Pharmacology 47 444-450
18. Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, Krammer PH, Peter ME & Dixit VM 1996 FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. Journal of Biological Chemistry 271 4961-4965
19. Cuvillier O 2002 Sphingosine in apoptosis signaling. Biochimica et Biophysica Acta 1585 153-162
20. Cuvillier O & Levade T 2003 Enzymes of sphingosine metabolism as potential pharmacological targets for therapeutic intervention in cancer. Pharmacological Research 47 439-445
21. Cuvillier O, Nava VE, Murthy SK, Edsall LC, Levade T, Milstien S & Spiegel S 2001 Sphingosine generation, cytochrome c release, and activation of caspase-7 in doxorubicin-induced apoptosis of MCF7 breast adenocarcinoma cells. Cell Death and Differentiation 8 162-171
22. Dawson MI, Chao WR, Pine P, Jong L, Hobbs PD, Rudd CK, Quick TC, Niles RM, Zhang XK, Lombardo A et al. 1995 Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Research 55 4446-4451
23. Dbaibo GS, El-Assaad W, Krikorian A, Liu B, Diab K, Idriss NZ, El-Sabban M, Driscoll TA, Perry DK & Hannun YA 2001 Ceramide generation by two distinct pathways in tumor necrosis factor alpha-induced cell death. FEBS Letters 503 7-12
24. Dbaibo GS, Pushkareva MY, Rachid RA, Alter N, Smyth MJ, Obeid LM & Hannun YA 1998 p53-dependent ceramide response to genotoxic stress. Journal of Clinical Investigation 102 329-339
25. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, Yun JK & Smith CD 2003 Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Research 63 5962-5969
26. Friedrichs K, Holzel F & Janicke F 2002 Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report. European Journal of Cancer 38 1730-1738
27. Gewirtz DA 2000 Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage. Breast Cancer Research and Treatment 62 223-235
28. Gidwani A, Brown HA, Holowka D & Baird B 2003 Disruption of lipid order by short-chain ceramides correlates with inhibition of phospholipase D and downstream signaling by FcepsilonRI. Journal of Cell Science 116 3177-3187
29. Gill JS & Windebank AJ 1997 Role of ceramide in suramin-induced cancer cell death. Cancer Letters 119 169-176
30. Glazer RI & Rohlff C 1994 Transcriptional regulation of multidrug resistance in breast cancer. Breast Cancer Research and Treatment 31 263-271
31. Goetzl EJ, Dolezalova H, Kong Y & Zeng L 1999 Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells. Cancer Research 59 4732-4737
32. Gouaze V, Mirault ME, Carpentier S, Salvayre R, Levade T & Adrieu-Abadie N 2001 Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells. Molecular Pharmacology 60 488-496
33. Gouaze V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE & Cabot MC 2004 Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Molecular Cancer Therapy 3 633-639
34. Green KA & Streuli CH 2004 Apoptosis regulation in the mammary gland. Cell Molecular Life Science 61 1867-1883
35. Gulbins E & Kolesnick R 2003 Raft ceramide in molecular medicine. Oncogene 22 7070-7077
36. Hannun YA & Bell RM 1989 Regulation of protein kinase C by sphingosine and lysosphingolipids. Clinica Chimica Acta 185 333-345
37. Hannun YA & Obeid LM 2002 The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. Journal of Biological Chemistry 277 25847-25850
38. Heinrich M, Neumeyer J, Jakob M, Hallas C, Tchikov V, Winoto-Morbach S, Wickel M, Schneider-Brachert W, Trauzold A, Hethke A & Schutze S 2004 Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation. Cell Death and Differentiation 11 550-563
39. Herrnring C, Reimer T, Jeschke U, Makovitzky J, Kruger K, Gerber B, Kabelitz D & Friese K 2000 Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochemistry and Cell Biology 113 189-194
40. Holthuis JC, Pomorski T, Raggers RJ, Sprong H & Van Meer G 2001 The organizing potential of sphingolipids in intracellular membrane transport. Physiological Reviews 81 1689-1723
41. Jaattela M, Benedict M, Tewari M, Shayman JA & Dixit VM 1995 Bcl-x and Bcl2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 10 2297-2305
42. Jatoi A, Suman VJ, Schaefer P, Block M, Loprinzi C, Roche P, Garneau S, Morton R, Stella PJ, Alberts SR, Pittelkow M, Sloan J & Pagano R 2003 A phase II study of topical ceramides for cutaneous breast cancer. Breast Cancer Research and Treatment 80 99-104
43. Jaumot M, Yan J, Clyde-Smith J, Sluimer J & Hancock JF 2002 The linker domain of the Ha-Ras hypervariable region regulates interactions with exchange factors, Raf-1 and phosphoinositide 3-kinase. Journal of Biological Chemistry 277 272-278
44. Jordan VC 2004 Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5 207-213
45. Keane MM, Ettenberg SA, Lowrey GA, Russell EK & Lipkowitz S 1996 Fas expression and function in normal and malignant breast cell lines. Cancer Research 56 4791-4798
46. Keane MM, Ettenberg SA, Nau MM, Russell EK & Lipkowitz S 1999 Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Research 59 734-741
47. Keely PJ 2001 Ras and Rho protein induction of motility and invasion in T47D breast adenocarcinoma cells. Methods in Enzymology 333 256-266
48. Keen JC & Davidson NE 2003 The biology of breast carcinoma. Cancer 97 825-833
49. Kester M & Kolesnick R 2003 Sphingolipids as therapeutics. Pharmacological Research 47 365-371
50. Kundu N, Smyth MJ, Samsel L & Fulton AM 2002 Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Research and Treatment 76 57-64
51. Lavie Y, Cao H, Bursten SL, Giuliano AE & Cabot MC 1996 Accumulation of glucosylceramides in multidrug-resistant cancer cells. Journal of Biological Chemistry 271 19530-19536
52. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE & Cabot MC 1997 Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. Journal of Biological Chemistry 272 1682-1687
53. Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DI, Chen S & Hsu CY 2004 Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. Journal of Cell Biology 164 123-131
54. Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM & Hannun YA 1998 Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. Journal of Biological Chemistry 273 11313-11320
55. Liu YY, Han TY, Giuliano AE & Cabot MC 1999 Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. Journal of Biological Chemistry 274 1140-1146
56. Liu YY, Han TY, Giuliano AE & Cabot MC 2001 Ceramide glycosylation potentiates cellular multidrug resistance. FASEB Journal 15 719-730
57. Liu YY, Han TY, Giuliano AE, Ichikawa S, Hirabayashi Y & Cabot MC 1999 Glycosylation of ceramide potentiates cellular resistance to tumor necrosis factor-alpha-induced apoptosis. Experimental Cell Research 252 464-470
58. Liu YY, Han TY, Yu JY, Bitterman A, Le A, Giuliano AE & Cabot MC 2004 Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells. Journal of Lipid Research 45 933-940
59. Lonning PE 2001 Stepwise estrogen suppression manipulating the estrostat. Journal of Steroid Biochemistry and Molecular Biology 79 127-132
60. Luberto C & Hannun YA 2000 Use of short-chain ceramides. Methods in Enzymology 312 407-420
61. Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, Hazen-Martin DJ, Obeid LM, Hannun YA & Smith GK 2002 Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. Journal of Biological Chemistry 277 41128-41139
62. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL & Cabot MC 1998 Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Research 18 475-480
63. Lucci A, Han TY, Liu YY, Giuliano AE & Cabot MC 1999 Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. International Journal of Oncology 15 541-546
64. Mandlekar S & Kong AN 2001 Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6 469-477
65. Manes S, Mira E, Gomez-Mouton C, Lacalle RA, Keller P, Labrador JP & Martinez AC 1999 Membrane raft microdomains mediate front-rear polarity in migrating cells. EMBO Journal 18 6211-6220
66. Marchesini N, Osta W, Bielawski J, Luberto C, Obeid LM & Hannun YA 2004 Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. Journal of Biological Chemistry 279 25101-25111
67. Maurer BJ, Melton L, Billups C, Cabot MC & Reynolds CP 2000 Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism. Journal of National Cancer Institute 92 1897-1909
68. Miller WR 1999 Biology of aromatase inhibitors: pharmacology/ endocrinology within the breast. Endocrine-Related Cancer 6 187-195
69. Nava VE, Hobson JP, Murthy S, Milstien S & Spiegel S 2002 Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Experimental Cell Research 281 115-127
70. Ogretmen B & Hannun YA 2004 Biologically active sphingolipids in cancer pathogenesis and treatment. Nature Review on Cancer 4 604-616
71. Perry DK, Carton J, Shah AK, Meredith F, Uhlinger DJ & Hannun YA 2000 Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. Journal of Biological Chemistry 275 9078-9084
72. Persidis A 1999 Cancer multidrug resistance. Nature Biotechnology 17 94-95
73. Pettus BJ, Chalfant CE & Hannun YA 2002 Ceramide in apoptosis: an overview and current perspectives. Biochimica et Biophysica Acta 1585 114-125
74. Pirianov G, Danielsson C, Carlberg C, James SY & Colston KW 1999 Potentiation by vitamin D analogs of TNFalpha and ceramide-induced apoptosis in MCF-7 cells is associated with activation of cytosolic phospholipase A2. Cell Death and Differentiation 6 890-901
75. Pommier Y, Sordet O, Antony S, Hayward RL & Kohn KW 2004 Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 23 2934-2949
76. Purohit A, Newman SP & Reed MJ 2002 The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Research 4 65-69
77. Rehman F, Shanmugasundaram P & Schrey MP 2004 Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity. British Journal of Cancer 91 1821-1828
78. Rosenwald AG & Pagano RE 1993 Intracellular transport of ceramide and its metabolites at the Golgi complex: insights from short-chain analogs. Advances in Lipid Research 26 101-118
79. Ruvolo PP 2003 Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacological Research 47 383-392
80. Sachs CW, Safa AR, Harrison SD & Fine RL 1995 Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. Journal of Biological Chemistry 270 26639-26648
81. Sakakura C, Sweeney EA, Shirahama T, Hagiwara A, Yamaguchi T, Takahashi T, Hakomori S & Igarashi Y 1998 Selectivity of sphingosine-induced apoptosis. Lack of activity of DL-erythyro-dihydrosphingosine. Biochemical and Biophysical Research Communication 246 827-830
82. Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M, Cordon-Cardo C, Schuchman EH, Fuks Z & Kolesnick R 1996 Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86 189-199
83. Scarlatti F, Bauvy C, Ventruti A, Sala G, Cluzeaud F, Vandewalle A, Ghidoni R & Codogno P 2004 Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1. Journal of Biological Chemistry 279 18384-18391
84. Scarlatti F, Sala G, Somenzi G, Signorelli P, Sacchi N & Ghidoni R 2003 Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB Journal 17 2339-2341
85. Schmelz EM, Sullards MC, Dillehay DL & Merrill AH Jr 2000 Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1, 2-dimethylhydrazine-treated CF1 mice. Journal of Nutrition 130 522-527
86. Schroepfer GJ Jr 2000 Oxysterols: modulators of cholesterol metabolism and other processes. Physiological Reviews 80 361-554
87. Selzner M, Bielawska A, Morse MA, Rudiger HA, Sindram D, Hannun YA & Clavien PA 2001 Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Research 61 1233-1240
88. Senchenkov A, Litvak DA & Cabot MC 2001 Targeting ceramide metabolism - a strategy for overcoming drug resistance. Journal of National Cancer Institute 93 347-357
89. Shabbits JA & Mayer LD 2002 P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Molecular Cancer Therapy 1 205-213
90. Shabbits JA & Mayer LD 2003 Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochimica et Biophysica Acta 1612 98-106
91. Sheen-Chen SM, Chen WJ, Eng HL & Chou FF 1997 Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Research and Treamentt 43 211-215
92. Signorelli P, Luberto C & Hannun YA 2001 Ceramide inhibition of NF-kappaB activation involves reverse translocation of classical protein kinase C (PKC) isoenzymes: requirement for kinase activity and carboxyl-terminal phosphorylation of PKC for the ceramide response. FASEB Journal 15 2401-2414
93. Silva J, Beckedorf A & Bieberich E 2003 Osteoblast-derived oxysterol is a migration-inducing factor for human breast cancer cells. Journal of Biological Chemistry 278 25376-25385
94. Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S & Sacchi N 2000 Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 19 1556-1563
95. Spiegel S & Milstien S 2000 Sphingosine-1-phosphate: signaling inside and out. FEBS Letters 476 55-57
96. Spiegel S, Olivera A, Zhang H, Thompson EW, Su Y & Berger A 1994 Sphingosine-1-phosphate, a novel second messenger involved in cell growth regulation and signal transduction, affects growth and invasiveness of human breast cancer cells. Breast Cancer Research and Treatment 31 337-348
97. Stover T & Kester M 2003 Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. Journal of Pharmacology and Experimental Therapeutics 307 468-475
98. Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y & Beckman BS 2004 Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. Journal of Pharmacology and Experimental Therapeutics 309 523-532
99. Strum JC, Small GW, Pauig SB & Daniel LW 1994 1-beta-D- Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells. Journal of Biological Chemistry 269 15493-15497
100. Tepper AW, Bubacco L & Canters GW 2002 Structural basis and mechanism of the inhibition of the type-3 copper protein tyrosinase from Streptomyces antibioticus by halide ions. Journal of Biological Chemistry 277 30436-30444
101. Turley JM, Fu T, Ruscetti FW, Mikovits JA, Bertolette DC & Birchenall-Roberts MC 1997 Vitamin E succinate induces Fas-mediated apoptosis in estrogen receptor-negative human breast cancer cells. Cancer Research 57 881-890
102. van Meer G, Sillence D, Sprong H, Kalin N & Raggers R 1999 Transport of (glyco)sphingolipids in and between cellular membranes; multidrug transporters and lateral domains. Bioscience Reports 19 327-333
103. Wang F, Nohara K, Olivera A, Thompson EW & Spiegel S 1999 Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate. Experimental Cell Research 247 17-28
104. Wang F, Van Brocklyn JR, Edsall L, Nava VE & Spiegel S 1999 Sphingosine-1-phosphate inhibits motility of human breast cancer cells independently of cell surface receptors. Cancer Research 59 6185-6191
105. Wang H, Giuliano AE & Cabot MC 2002 Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells. Molecular Cancer Therapy 1 719-726
106. Zhang Y, Mattjus P, Schmid PC, Dong Z, Zhong S, Ma WY, Brown RE, Bode AM & Schmid HH 2001 Involvement of the acid sphingomyelinase pathway in uva-induced apoptosis. Journal of Biological Chemistry 276 11775-11782